BiotechTube
GlioCure

GlioCure

Paris, France· Est.
gliocure.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

GlioCure is a private, preclinical-stage biotech targeting glioblastoma and other solid tumors through a novel peptide platform. Its lead asset, GC01.1, is a βIII-tubulin-targeting peptide in late non-regulatory preclinical development, with three patent families supporting its pipeline. The company is led by an experienced bio-entrepreneur and a neuroscience researcher, having raised €3 million since inception to advance its neuro-oncology programs.

Neuro-oncologyOncology

Technology Platform

Platform based on novel peptides derived from neurofilament proteins, selectively targeting cells overexpressing βIII-tubulin. Offers dual antitumor and neuroprotective mechanism of action.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The primary opportunity is addressing the dire unmet need in glioblastoma, a market with poor survival outcomes and limited treatment options.
The platform's potential expansion into other βIII-tubulin-positive cancers, like triple-negative breast cancer, significantly broadens the addressable market.
The neuroprotective effect could be a key differentiator for quality of life and regulatory approval.

Risk Factors

The company is at a high-risk, preclinical stage where many compounds fail to translate to human efficacy.
Securing sufficient funding to advance into costly clinical trials is a major hurdle.
The scientific challenge of effectively delivering a peptide therapeutic across the blood-brain barrier to treat brain tumors remains a significant technical risk.

Competitive Landscape

GlioCure operates in the highly competitive glioblastoma space, competing with large pharma, biotech, and academic efforts across modalities including immunotherapy, targeted therapy, and drug delivery technologies. Its niche is a peptide targeting βIII-tubulin with a claimed neuroprotective effect, which is a less crowded approach compared to areas like checkpoint inhibitors or CAR-T.

More companies in RNA Therapeutics (non-mRNA) →More companies in France →